Alpha Cognition Secures Patent for Traumatic Brain Injury Treatment Until 2045
Alpha Cognition announced the USPTO has issued a patent which includes claims covering methods of treating both confirmed and suspected traumatic brain injury using ALPHA-1062. This newly issued patent strengthens Alpha Cognition's intellectual property portfolio and complements existing patents supporting both ALPHA-1062 and Zunveyl. The patent provides protection through 2045.
